PD1 knock-down anti-CD19 CAR-T cells

PD1 knock-down anti-CD19 CAR-T cells are a form of chimeric antigen receptor T cell (CAR-T) therapy engineered to target the CD19 antigen on B cells while simultaneously reducing or eliminating expression of the programmed death-1 (PD-1) immune checkpoint receptor. The primary mechanism involves genetic modification—often via CRISPR/Cas9 or other gene-editing technologies—to disrupt the PDCD1 gene encoding PD-1 in T cells that have been further modified to express an anti-CD19 chimeric antigen receptor. This dual engineering aims to enhance antitumor activity by preventing tumor-induced exhaustion and inhibition of the infused T cells, thereby improving their persistence and cytotoxicity against malignant B lymphocytes. These therapies are being developed primarily for relapsed/refractory B cell non-Hodgkin lymphoma and other CD19-positive hematologic malignancies[1][3]. Early clinical data suggest improved efficacy compared to conventional CD19-targeted CAR-T therapies due to resistance against immunosuppressive signals from the tumor microenvironment[3]. However, preclinical studies indicate that complete loss of PD-1 may also increase risk for functional exhaustion and reduced survival of therapeutic T cells under certain conditions[2].

Other names

PD-1 knockout anti-CD19 CAR-T cellsPD1 knockout anti-CD19 CAR-T cellsPD 1 knockout anti-CD19 CAR-T cellsPD-1 gene-edited anti-CD19 CAR-T cellsPD1 gene-edited anti-CD19 CAR-T cellsPD 1 gene-edited anti-CD19 CAR-T cellsCD19 CAR-T with PD-1 knockdownCD-19 CAR-T with PD-1 knockdownCD 19 CAR-T with PD-1 knockdown